Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis

Overview

To evaluate the therapeutic equivalence of the Test formulation, econazole nitrate cream, 1% to the Reference product, econazole nitrate cream, 1% in the treatment of tinea pedis. To demonstrate the superiority of the Test and Reference (active) treatments over Placebo treatment in patients with tinea pedis. To compare the safety of Test, Reference and Placebo treatments in patients with tinea pedis.

Full Title of Study: “Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 17, 2016

Interventions

  • Drug: Econazole Nitrate Cream, 1%
  • Drug: Placebo

Arms, Groups and Cohorts

  • Experimental: Test
    • Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
  • Active Comparator: Reference Standard
    • Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
  • Placebo Comparator: Placebo
    • Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure
    • Time Frame: Day 42
    • To be considered a Therapeutic Cure, the patient must have both Clinical Cure (patient’s total severity score must be ≤ 2 with no individual severity score > 1) and Mycological Cure (patient must have a negative KOH test and a negative fungal culture) of tinea pedis
  • Proportion of Patients in Each Treatment Group Who Are Considered a Therapeutic Cure
    • Time Frame: Day 42
    • To be considered a Therapeutic Cure, the patient must have both Clinical Cure (patient’s total severity score must be ≤ 2 with no individual severity score > 1) and Mycological Cure (patient must have a negative KOH test and a negative fungal culture) of tinea pedis

Secondary Measures

  • Proportion of Patients in Each Active Treatment Group Who Are Considered a Clinical Cure (Patient’s Total Severity Score Must be ≤ 2 With no Individual Severity Score > 1)
    • Time Frame: Day 42
    • The following Clinical Signs and Symptoms of a target lesion with tinea pedis are individually rated for severity (none, mild, moderate, or severe): fissuring/cracking, erythema, maceration, scaling, pruritus, and burning/stinging
  • Proportion of Patients in Each Active Treatment Group Who Are Considered a Mycological Cure
    • Time Frame: Day 42
    • To be considered a mycological cure the patient must have a negative KOH test and a negative fungal culture for T. rubrum, T. mentagrophytes or E. floccosum
  • Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Cure (Patient’s Total Severity Score Must be ≤ 2 With no Individual Severity Score > 1)
    • Time Frame: Day 42
    • The following Clinical Signs and Symptoms of a target lesion with tinea pedis are individually rated for severity (none, mild, moderate, or severe): fissuring/cracking, erythema, maceration, scaling, pruritus, and burning/stinging
  • Proportion of Patients in Each Treatment Group Who Are Considered a Mycological Cure
    • Time Frame: Day 42
    • To be considered a mycological cure the patient must have a negative KOH test and a negative fungal culture for T. rubrum, T. mentagrophytes or E. floccosum

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male or non-pregnant, non-lactating female ≥ 18 years of age. – Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin). – Provisionally confirmed at baseline by a positive potassium hydroxide (KOH) wet mount preparation – Total score ≥ 4 for the clinical signs and symptoms of tinea pedis in the target area. In addition the target area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritus or scaling. Exclusion Criteria:

  • Presence of any other infection of the foot or other disease process that, in the Investigator's opinion, may interfere with the evaluation of the patient's tinea pedis – History of or current psoriasis, Lichen planus or contact dermatitis involving the feet within the previous 12 months. – Past history of dermatophyte infections with a lack of response to antifungal therapy – Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface or onychomycosis involving ≥ 20% of the area of either great toenail and/or involving more than five toenails in total or other concurrent dermatophytoses (e.g., tinea cruris) and any other skin disease to an extent that, in the opinion of the investigator, might interfere with the evaluation of tinea pedis or study results

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mylan Inc.
  • Collaborator
    • DPT Laboratories, Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.